Congrats to the 2022 Click Chemistry Nobel Prize Winners!
The 2022 Nobel Prize in Chemistry was jointly awarded to Barry Sharpless, Morten Meldal, and Carolyn Bertozzi for pioneering click chemistry and bioorthogonal chemistry, groundbreaking methods that simplify molecular assembly and enable precise drug discovery and bioconjugation applications, with practical implementations such as Dotmatics’ biological registration system supporting automated, high-throughput creation of click chemistry-based molecular designs.
Last week, the Nobel prize announced winners of its chemistry prize. This year three chemistry visionaries shared it jointly for their work on the development of click chemistry and bioorthogonal chemistry—Barry Sharpless and Morten Meldal, and Carolyn Bertozzi.
“Click chemistry” aligns with the Nobel Prize Teams’ 2022 focus of simplifying chemistry’s complexity and making difficult processes easier, more reliable and with less unwanted byproducts. Barry Sharpless and Morten Meldal laid the click chemistry foundation in which molecular building blocks snap together quickly and efficiently, whilst Carolyn Bertozzi took the form to a new dimension and started utilizing it in living organisms. Meldal best distilled the utility and the simplicity of the reaction as building complex structures and linking them together like Legos.
The field of click chemistry and bioorthogonal chemistry has wide applicability for drug discovery, particularly with regard to bioconjugation, an increasingly relevant concept supporting existing (e.g. antibody drug conjugates) and driving new drug modalities. It can be used to explore cells, map DNA and design drugs that can target diseases more precisely. In addition to it currently being harnessed to improve the targeting of cancer pharmaceuticals now being tested in clinical trials, click also holds promise with a host of health, agricultural and industrial applications.
Dotmatics’ biological registration system includes click chemistry capabilities. It can automate creating click chemistry crosslinking between components of a registration record. User-defined click monomers enable cycloaddition chemistry methods and are extendable to include other types of click chemistry reactions. These tools enable high-throughput record creation and ensure the fidelity of those molecular designs utilizing click-crosslinks.
Congratulations to the three 2022 Nobel Prize winners for chemistry and for all the winners for their scientific work and achievement. We're honored to be working with many of these Nobel Laureate organizations.
Related
ABC News: How AI is Transforming Drug Discovery
Christian Olsen, VP of Biologics at Dotmatics, explains in an ABC News interview how AI is transforming pharmaceutical R&D by accelerating drug target identification and high-throughput screening, thereby significantly reducing the time and cost of drug discovery and enabling breakthroughs in diseases like cancer, diabetes, cardiovascular conditions, and neurology.
Our 11 Most-Read Blogs of 2023: AI, Biologics, ELNs, and More
Dotmatics' top blogs of 2023 highlight key scientific advancements including the convergence of small molecule and biologic drug development, the integration and comparison of LIMS and ELN systems for enhanced lab data management, and strategies to minimize human errors in biologics research through automation and calibration.
Ultimate Benchling Comparison Guide
The guide highlights Benchling's limitations in data value, lab automation, and tool breadth for life sciences and chemicals industries, presenting Dotmatics as a superior alternative with advanced digitization, AI-driven data capture, multimodal discovery capabilities, comprehensive chemistry features, and broad integration support, serving 10,000 customers and 2 million scientists globally across various research sectors.
The Rise of Biotech: Why Smaller Companies Are Outpacing Big Pharma on Innovation
Smaller biotech companies are increasingly outpacing big pharmaceutical firms in new molecular entity approvals due to their greater agility, willingness to take risks, and freedom to innovate despite funding challenges, with over half of upcoming blockbuster drug launches expected from first-time launchers who face higher risks but also potential for significant success.
Prioritizing Data Integrity in R&D: Challenges and Best Practices
The article emphasizes the critical importance of maintaining data integrity in R&D by implementing robust data governance, security, and management practices throughout the research lifecycle to ensure data accuracy, protect patient safety, uphold product efficacy, and comply with regulatory standards amid increasing digitization and evolving threats.
From Fragmented Data to Unified Discovery: LifeArc's Approach to Multimodal R&D
LifeArc, a UK-based medical charity focused on transformative life science, has developed a collaborative, multidisciplinary R&D approach that integrates diverse data from over 100 internal scientists, external pharma, biotech, academic partners, and CROs across multiple therapeutic modalities—including small molecules and biologics like engineered antibodies—to streamline drug discovery and design for diseases such as cancer, Crohn’s disease, multiple sclerosis, rheumatoid arthritis, and COVID-19, enabling unified data flow and informed, data-driven decision-making that has already resulted in four licensed medications and several drugs in trials.